Painreform Ltd (PRFX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Painreform Ltd (PRFX) has a cash flow conversion efficiency ratio of -0.117x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-991.00K) by net assets ($8.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PRFX market cap for the company's overall valuation and market capitalisation.
Painreform Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Painreform Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Painreform Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Painreform Ltd ranked by their cash flow conversion efficiency. Explore PRFX cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Regional REIT Ltd
LSE:RGL
|
0.026x |
|
Pantheon Resources
LSE:PANR
|
0.006x |
|
DevvStream Corp. Common Stock
NASDAQ:DEVS
|
0.150x |
|
NTR Holding A/S
CO:NTR-B
|
-0.080x |
|
Zhibao Technology Inc. Class A Ordinary Shares
NASDAQ:ZBAO
|
-1.705x |
|
Oldfields Holdings Ltd
AU:OLH
|
-0.443x |
|
Jianzhi Education Technology Group Company Limited American Depositary Shares
NASDAQ:JZ
|
0.428x |
|
Mobico Group Plc
LSE:MCG
|
-1.446x |
Annual Cash Flow Conversion Efficiency for Painreform Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Painreform Ltd from 2017 to 2024. View Painreform Ltd (PRFX) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.82 Million | $-12.62 Million | -6.919x | -649.96% |
| 2023-12-31 | $7.24 Million | $-6.68 Million | -0.923x | -57.43% |
| 2022-12-31 | $11.02 Million | $-6.46 Million | -0.586x | -61.72% |
| 2021-12-31 | $18.08 Million | $-6.55 Million | -0.362x | -135.56% |
| 2020-12-31 | $16.62 Million | $-2.56 Million | -0.154x | -242.03% |
| 2019-12-31 | $-5.62 Million | $-609.00K | 0.108x | -23.97% |
| 2018-12-31 | $-4.46 Million | $-635.00K | 0.142x | -40.57% |
| 2017-12-31 | $-3.63 Million | $-870.00K | 0.240x | -- |
About Painreform Ltd
PRF Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinica… Read more